Document Type
Article
Publication Date
1-1-2023
Original Citation
Axtman A,
Brennan P,
Frappier-Brinton T,
Betarbet R,
Carter GW,
Fu H,
Gileadi O,
Greenwood A,
Leal K,
Longo F,
Mangravite L,
Edwards A,
Levey A,
.
Open drug discovery in Alzheimer's disease. Alzheimers Dement (N Y). 2023;9(2):e12394.
Keywords
JMG
JAX Source
Alzheimers Dement (N Y). 2023;9(2):e12394.
ISSN
2352-8737
PMID
37215505
DOI
https://doi.org/10.1002/trc2.12394
Abstract
Alzheimer's disease (AD) drug discovery has focused on a set of highly studied therapeutic hypotheses, with limited success. The heterogeneous nature of AD processes suggests that a more diverse, systems-integrated strategy may identify new therapeutic hypotheses. Although many target hypotheses have arisen from systems-level modeling of human disease, in practice and for many reasons, it has proven challenging to translate them into drug discovery pipelines. First, many hypotheses implicate protein targets and/or biological mechanisms that are under-studied, meaning there is a paucity of evidence to inform experimental strategies as well as high-quality reagents to perform them. Second, systems-level targets are predicted to act in concert, requiring adaptations in how we characterize new drug targets. Here we posit that the development and open distribution of high-quality experimental reagents and informatic outputs-termed target enabling packages (TEPs)-will catalyze rapid evaluation of emerging systems-integrated targets in AD by enabling parallel, independent, and unencumbered research.
Comments
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.